Results for central venous catether translation from English to Maltese

a central venous catheter is not required.
m’hemmx bżonn ta’ kateter fil-vina ċentrali.

related to central venous access devices (cvad)
relatati ma’ tagħmir għal aċċess venuż ċentrali cvad)

busilvex should be administered by intravenous infusion via central venous catheter.
busilvex għandu jingħata permezz ta’ infużjoni minn ġol-ġilda permezz ta’ kateter ġol-vina ċentrali.

therefore, in subsequent studies posaconazole was administered via central venous catheter.
għalhekk, fl-istudji sussegwenti posaconazole ngħata permezz ta’ kateter venuż ċentrali.

symptomatic thromboses related to the use of central venous catheters have been described, too.
trombożijiet sintomatiċi relatati mal-użu ta’ kateters venużi ċentrali ġew deskritti wkoll.

during the ilp, central venous pressure and arterial pressure monitoring is strongly recommended.
matul l-ilp, hu rakkomandat ħafna li jkun hemm monitoraġġ tal-pressjoni tal-vini ċentrali u tal- pressjoni arterjali.

the use of central venous access is strongly recommended (see section 4.2).
l-użu ta’ aċċess ċentrali venuż huwa rakkomandat bil-qawwa (ara sezzjoni 4.2).

administration through a central venous line is strongly recommended (see section 6.6).
għoti minn ġo linja venuża ċentrali huwa rakkomandat bil- qawwa (ara sezzjoni 6. 6).

some serious infections and sepsis were related to the use of central venous catheters (cvcs).
Ċerti infezzjonijiet serji u sepsis kienu relatati mal-użu ta' katiters ġol-vini ċentrali (cvcs).

coagulation disorders including symptomatic thrombosis related to the use of central venous catheters, hyperglycaemic conditions.
disturbi fil-koagulazzjoni li jinkludu trombożi sintomatika relatata mal-użu ta’ kateters venużi ċentrali, kundizzjonijiet ipergliċemiċi.

signs of circulatory overload should be carefully monitored or central venous pressure (cvp) measured.
sinjali ta’ tagħbija ċirkolatorja żejda għandhom jiġu mgħassa b’attenzjoni jew għandha tiġi mkejla l-pressjoni venuża ċentrali (cvp) (ġiet irreġistrata żjieda fil-cvp fil-klieb kollha trattati kull meta ġiet imkejjla).

xigris should be administered via a dedicated intravenous line or a dedicated lumen of a multilumen central venous catheter.
xigris għandu jingħata permezz ta’ linja minn ġol-vina apposta jew lumen apposta ta’ kateter ċentrali fil-vina multilumen.

if a central venous catheter is not available, a single infusion may be administered through a peripheral venous catheter.
jekk ma jkunx disponibbli kateter venuż ċentrali, tista’ tingħata infużjoni waħda permezz ta’ kateter venuż ċentrali.

a central venous access device (cvad) may become necessary to allow frequent infusions of factor viii products.
tagħmir għal aċċess venuż ċentral (cvad) jista’ jsir neċessarju biex jippermetti infużjonijiet frekwenti ta’ prodotti ta’ fattur viii.

the recommended dosage should be administered by intravenous infusion although it has been administered via a central venous catheter in ongoing clinical trials.
id- dożaġġ rrakkomandat għandu jingħata permezz ta 'infużjoni għal ġol- vini għalkemm kien mogħti permezz ta ’ kateter minn ġol- vina ċentrali f’ provi kliniċi kontinwi.

if a central venous catheter was not readily available, patients could receive a single infusion over 30 minutes via a peripheral venous catheter.
jekk ma jkunx disponibbli minnufih kateter venuż ċentrali, il-pazjenti jistgħu jirċievu infużjoni waħda fuq perjodu ta’ 30 minuta permezz ta’ kateter venuż periferali.

for study purposes, patients with extravasations from a central venous access device (cvad) were not included in the efficacy evaluation.
għal skopijiet ta’ studju, pazjenti b’ekstravazzazzjonijiet minn tagħmir għall-aċċess venuż ċentrali (cvad – central venous access device) ma ġewx inklużi fl-evalwazzjoni dwar l-effikaċja.

it is recommended that yondelis be given through a central venous line (a thin tube leading from the skin into the large veins just above the heart).
huwa rrakkomandat li yondelis jingħata mil-linja venuża ċentrali (permezz ta’ tubu dejjaq li jwassal mill-ġilda għall-vini l- kbar, eżatt ’l fuq mill-qalb).

patients typically have a central venous catheter in situ and as a consequence of prior asct are likely to be immunocompromised during therapy, and therefore, at risk of developing systemic infection.
il-pazjenti tipikament ikollhom kateter venuż ċentrali in situ u bħala konsegwenza ta’ asct fil-passat, x’aktarx li se jkunu immunokompromessi matul it-terapija, u għalhekk, f’riskju li jiżviluppaw infezzjoni sistematika.

for minor surgery such as central venous access port placement, biopsy, and tooth extraction, aflibercept may be initiated/restarted once the surgical wound is fully healed.
fil-każ ta’ kirurġija minuri bħal tqegħid tal-punt ċentrali ta’ aċċess għal vina, bijopsija, u l-qligħ tas-snien, aflibercept jista jinbeda/jerġa’ jinbeda ladarba l-feriti kirurġiċi jkunu kompletament imfejqa.